MX2018012511A - Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr. - Google Patents

Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.

Info

Publication number
MX2018012511A
MX2018012511A MX2018012511A MX2018012511A MX2018012511A MX 2018012511 A MX2018012511 A MX 2018012511A MX 2018012511 A MX2018012511 A MX 2018012511A MX 2018012511 A MX2018012511 A MX 2018012511A MX 2018012511 A MX2018012511 A MX 2018012511A
Authority
MX
Mexico
Prior art keywords
treatment
neoplasms
combinations
cell targeting
egfr inhibitors
Prior art date
Application number
MX2018012511A
Other languages
English (en)
Inventor
Vilenchik Maria
Frid Michael
Kuznetsova Alexandra
Gankin Yuriy
Duey Marc
Original Assignee
Felicitex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Felicitex Therapeutics Inc filed Critical Felicitex Therapeutics Inc
Publication of MX2018012511A publication Critical patent/MX2018012511A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona composiciones y métodos para el tratamiento de neoplasias, en particular, mediante la localización de células cancerosas en estado quiescente, o en reposo, con agentes terapéuticos en combinación con otros tratamientos eficaces contra ciertas afecciones neoplásicas, en particular, tratamiento anticanceroso con agentes inhibidores de EGFR.
MX2018012511A 2016-04-15 2017-04-14 Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr. MX2018012511A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662323537P 2016-04-15 2016-04-15
PCT/US2017/027719 WO2017181075A1 (en) 2016-04-15 2017-04-14 Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors

Publications (1)

Publication Number Publication Date
MX2018012511A true MX2018012511A (es) 2019-07-08

Family

ID=60039950

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018012511A MX2018012511A (es) 2016-04-15 2017-04-14 Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
MX2023000549A MX2023000549A (es) 2016-04-15 2018-10-12 Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023000549A MX2023000549A (es) 2016-04-15 2018-10-12 Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.

Country Status (11)

Country Link
US (3) US10322128B2 (es)
EP (1) EP3442505A4 (es)
JP (2) JP7123806B2 (es)
KR (2) KR102494174B1 (es)
CN (1) CN109562176A (es)
AU (2) AU2017248762A1 (es)
BR (1) BR112018071031A2 (es)
CA (1) CA3021021A1 (es)
IL (2) IL262323B (es)
MX (2) MX2018012511A (es)
WO (1) WO2017181075A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4349410A3 (en) * 2016-01-05 2024-06-05 The Trustees Of Columbia University In The City Of New York A composition for use in the therapeutic treatment of a cancer or a tumor
KR102494174B1 (ko) * 2016-04-15 2023-02-02 펠리시텍스 쎄라퓨틱스, 인코포레이티드 정지 세포 표적화 및 egfr 억제제를 이용하는 신생물 치료를 위한 조합
US10314843B2 (en) 2016-04-15 2019-06-11 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis
JP2022534881A (ja) * 2019-05-22 2022-08-04 ボロノイ・カンパニー・リミテッド がんの予防および／または処置のためのピロロ－ピリジン誘導体化合物の新規な使用
JP2024523861A (ja) * 2021-06-15 2024-07-02 ジェネンテック， インコーポレイテッド がんを処置するための併用療法におけるｅｇｆｒ阻害剤およびｐｅｒｋ活性化剤、ならびにこれらの使用
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
CN115947673B (zh) * 2022-12-19 2024-03-15 湖南岳靶生物医药有限公司 一种化疗药物增敏剂、组合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2744797E (pt) 2011-08-19 2015-11-16 Diaxonhit Inibidores de dyrkl e suas utilizações
EP2560004A1 (de) * 2011-08-19 2013-02-20 DST Diagnostische Systeme & Technologien GmbH Neues PoC-Testsystem und Verfahren
JP2015534584A (ja) 2012-10-10 2015-12-03 フェリシテックス・セラピューティクス，インコーポレイテッド 静止癌細胞の標的化による癌の治療
CA2854542A1 (en) * 2013-06-18 2014-12-18 4Sc Discovery Gmbh Method of inhibiting dyrk1b
WO2015143380A1 (en) 2014-03-20 2015-09-24 Samumed, Llc 5-substituted indazole-3-carboxamides and preparation and use thereof
AU2015313811A1 (en) 2014-09-08 2017-04-06 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
WO2016055916A1 (en) * 2014-10-06 2016-04-14 Novartis Ag Therapeutic combination for the treatment of cancer
AU2015402778B2 (en) 2015-07-23 2020-10-29 Calgent Biotechnology Co., Ltd. Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
KR102494174B1 (ko) 2016-04-15 2023-02-02 펠리시텍스 쎄라퓨틱스, 인코포레이티드 정지 세포 표적화 및 egfr 억제제를 이용하는 신생물 치료를 위한 조합
US10314843B2 (en) 2016-04-15 2019-06-11 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis

Also Published As

Publication number Publication date
CA3021021A1 (en) 2017-10-19
AU2017248762A1 (en) 2018-11-01
US20220110940A1 (en) 2022-04-14
US10322128B2 (en) 2019-06-18
US20170296541A1 (en) 2017-10-19
IL262323A (en) 2018-11-29
IL262323B (en) 2022-03-01
KR102494174B1 (ko) 2023-02-02
MX2023000549A (es) 2023-02-13
JP2019511554A (ja) 2019-04-25
KR20230020565A (ko) 2023-02-10
BR112018071031A2 (pt) 2019-02-12
EP3442505A4 (en) 2019-12-18
US11202779B2 (en) 2021-12-21
JP2022145800A (ja) 2022-10-04
AU2023200428A1 (en) 2023-03-02
EP3442505A1 (en) 2019-02-20
US20190298723A1 (en) 2019-10-03
KR20180132882A (ko) 2018-12-12
JP7123806B2 (ja) 2022-08-23
CN109562176A (zh) 2019-04-02
WO2017181075A1 (en) 2017-10-19
IL288777A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
MX2019011431A (es) Inhibidores de proteina 1 de muerte celular programada (pd-1)/ligando 1 de muerte programada (pd-l1).
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
PH12017502391A1 (en) Compositions and methods for inhibiting arginase activity
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
MA39906A (fr) Polythérapies pour le traitement du cancer
MX2017010595A (es) Métodos, composiciones, y equipos para tratamiento de cáncer.
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
MX2020001727A (es) Terapia de combinacion.
MX2019013862A (es) Terapia de combinacion.
MX2017011018A (es) Inhibicion de la actividad de olig2.
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
WO2017019721A3 (en) Combinations of ezh2 inhibitors with further agents for use in the treatment of cancer
ZA201901367B (en) Inhibition of olig2 activity
PH12016501838A1 (en) Compounds and their methods of use
WO2018081817A3 (en) Targeting microrna-101-3p in cancer therapy
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2022012146A (es) Combinaciones para el tratamiento de neoplasias utilizando localizacion de celulas quiescentes e inhibidores de la mitosis.
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
EA201592012A8 (ru) Применение флагеллина для улучшенной химиотерапии
EA201992045A1 (ru) Ингибиторы pd-1/pd-l1
EA201691907A1 (ru) Комбинированная терапия кураксинами